Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000104

Chief Executive Officer sold 25,000 shares at an average $83.62 ($2,090,593)

  • Chief Executive Officer acquired 25,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Klein Lawrence Otto Chief Executive Officer 2026-10-01 Option exercise 10b5-1 +25,000 $7.80 $195,000 948,128 D
Klein Lawrence Otto Chief Executive Officer 2026-10-01 Sale 10b5-1 −16,246 $83.40 $1,354,882 931,882 D
Klein Lawrence Otto Chief Executive Officer 2026-10-01 Sale 10b5-1 −8,554 $84.03 $718,755 923,328 D
Klein Lawrence Otto Chief Executive Officer 2026-10-01 Sale 10b5-1 −200 $84.78 $16,956 923,128 D
Derivatives
Klein Lawrence Otto Chief Executive Officer 2026-10-01 Option exercise · Employee Warrant (right to buy) 10b5-1 −25,000 1,528,513 D
Open-market sales · 25,000 sh · avg $83.62 · $2,090,593
Loading xslF345X06/form4.xml…